OfficeHours

JUNE 6, 2023

They may then negotiate with the company to restructure the debt, provide additional capital, or facilitate a turnaround. Going public through an IPO is one of the most well-known and potentially lucrative exit strategies for private equity firms.

Private Equity 147

Private Equity Equities Debt Investment 147

The TRADE

JUNE 23, 2023

EU asset managers, banks and brokers are urging policy markets not to succumb to pressure that could potentially lead to suboptimal outcomes in the Markets in Financial Instruments Directive (Mifid/r) review.

Trading 59

Trading Equities Asset Management Initial Public Offering 59

Cooley M&A

OCTOBER 29, 2020

is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. A distinct feature of SPAC 3.0

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

2022 drivers and headwinds Choppy access to capital markets and financing to fund ongoing operations Many life sciences companies faced challenges raising money in the capital markets in 2022. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. 2021’s SPAC activity was most intense in the first quarter, with 298 SPAC IPOs priced and 97 deSPAC transactions announced in the first quarter alone.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

FEBRUARY 15, 2017

We expect this trend to continue, with mid-market and smaller deals driving the deal count in 2017. Dealmakers appear much more optimistic in the first quarter of 2017 than at this same time last year, in part because of greater optimism about the IPO market and the potential for favorable corporate tax and other regulatory changes.

M&A 40

M&A IPO Pharmaceutical Valuation 40